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Abstract 
Growth hormone receptor knockout (GHR-KO) mice are long lived with improved 
healthspan, making this an excellent model system for understanding biochemical 
mechanisms important to cognitive reserve.  The purpose of the present study was to 
elucidate differences in cognition and glutamatergic dynamics between aged (20-24 
month-old) GHR-KO and littermate controls.  Glutamate plays a critical role in 
hippocampal learning and memory and is implicated in several neurodegenerative 
disorders, including Alzheimer’s disease.  Spatial learning and memory were assessed 
using the Morris water maze (MWM), while independent dentate gyrus (DG), CA3 and 
CA1 basal glutamate, release, and uptake measurements were conducted in isoflurane 
anesthetized mice utilizing an enzyme-based microelectrode array (MEA) coupled with 
constant potential amperometry.  These MEAs have high temporal and low spatial 
resolution while causing minimal damage to the surrounding parenchyma.  Littermate 
controls performed worse on the memory portion of the MWM behavioral task and had 
elevated DG, CA3 and CA1 basal glutamate and stimulus-evoked release compared with 
age-matched GHR-KO mice.  CA3 basal glutamate negatively correlated with MWM 
performance.  These results support glutamatergic regulation in learning and memory and 
may have implications for therapeutic targets to delay the onset of, or reduce cognitive 
decline, in Alzheimer’s disease.   
Keywords:   healthspan, longevity, biosensor, electrode, Alzheimer’s disease  
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1.  Introduction 
Growth hormone (GH) is secreted by the anterior pituitary gland and binds to its receptor 
ubiquitously expressed throughout the mammalian reproductive, muscular, endocrine, 
and nervous systems, where it regulates growth and metabolism often mediated through 
insulin-like growth factor-I (IGF-1)1.  The GH/IGF-1 axis is regarded as an important 
regulator in aging such that attenuated signaling increases lifespan2, potentially by 
providing protection against cancer, diabetes, and neurodegeneration3.  This is supported 
by GH receptor knockout (GHR-KO) mice that exhibit increased lifespan (30-36 months) 
and improved healthspan (reduced and delayed incidence of neoplasty, protection from 
diet-induced nephropathy, and retained cognitive abilities).  Furthermore, inhibition of GH 
has been shown to increase neuronal differentiation4 and GHR-KO mice have an 
approximate 25% increase in total neuron cell density in the cortex.5 However these 
benefits come at a concession of decreased size with increased adiposity, similar to Laron 
Syndrome6–10.   
The increased lifespan of GHR-KO mice make them an excellent model system for 
studying age-related cognitive reserve and neurotransmitter regulation in comparison to 
littermate controls.  For example, recent data support that GHR-KO mice maintain 
hippocampal glutamatergic function from 4-22 months of age, including vesicular 
glutamate transporter (VGLUT) 1 (the predominant hippocampal VGLUT located in 
classical excitatory terminals11) and 3, glutamate transporter 1 (GLT-1), and the N-methyl-
D-aspartate (NMDA) receptor subtype GluN2B12.  Glutamate, the predominant excitatory 
neurotransmitter in the mammalian CNS, has a strong prevalence in neocortical and 
hippocampal pyramidal neurons; therefore, playing a critical role in learning and 
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memory13.  Because of this, glutamate dysregulation has been implicated in age-related 
cognitive decline associated with neurodegenerative disorders such as Alzheimer’s 
disease13–17. 
The purpose of the present study was to elucidate differences in cognition and 
glutamatergic dynamics between aged (20-24 month-old) GHR-KO and age-matched 
littermate controls.  Spatial learning and memory was assessed using the Morris water 
maze (MWM) behavioral paradigm18–20. Extracellular glutamate dynamics were studied 
in the dorsal hippocampus since this region is important for consolidation and retrieval of 
spatial memory21.  Glutamate measurements were conducted utilizing an enzyme-based 
microelectrode array (MEA) coupled with constant potential amperometry to 
independently measure basal glutamate and stimulus-evoked glutamate release, and 
uptake in the dentate gyrus (DG), CA3, and CA1 of isoflurane anesthetized littermate 
controls  and GHR-KO mice.  These MEAs have high temporal (4 Hz)22 and low spatial 
resolution (50 x 100 µm) while causing minimal damage to the surrounding parenchyma 
(50-100 microns)23.  The results presented here support the importance of glutamatergic 
regulation for learning and memory in the GHR-KO mouse model of successful aging.  
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2.  Methods 
2.1  Animals  
Female GHR-KO (20-24 months of age) and age-matched female normal littermate 
controls, were produced in a breeding colony maintained at Southern Illinois University 
School of Medicine.  This colony was established by crossing 129Ola/BALB/c GHR +/- 
breeders24 provided by Dr. John J. Kopchick with mice derived from crosses of C57BL/6J 
and C3H/J strains and maintained as a closed colony with inbreeding minimized by 
avoiding brother x sister matings25.  Protocols for animal use were approved by the 
Laboratory Animal Care and Use Committee at Southern Illinois University School of 
Medicine.  Animals were group housed on a 12:12 hour light: dark cycle, and food and 
water were available ad libitum.  Each mouse underwent cognitive assessment, in vivo 
glutamate recordings, and post mortem histological analysis of brain tissue with the 
exception of a loss of two GHR-KO mice that occurred after MWM due to complications 
during surgery prior to in vivo electrochemistry.  Immediately following in vivo glutamate 
recordings, mice were euthanized with an overdose of isoflurane and decapitated.  Upon 
decapitation, 5 mm tail snips were collected and stored at -80°C until shipment to 
TransnetYX®, Inc (Cordova, TN) for genotype verification. 
2.2  Chemicals  
All chemicals were prepared and stored according to manufacturer recommendations 
unless otherwise noted.  L-glutamate oxidase (EC 1.4.3.11) was obtained from Cosmo 
Bio Co. (Carlsbad, CA) and diluted in distilled, deionized water to make a 1U/µl stock 
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solution that was stored at 4°C.  Sodium phosphate monobasic monohydrate, sodium 
phosphate dibasic anhydrous, 1,3-phenylenediamine dihydrochloride (mPD), sodium 
chloride, calcium chloride dehydrate, and hydrogen peroxide (H2O2, 30% in water) were 
obtained from Thermo Fisher Scientific (Waltham, MA).  L-glutamic acid sodium salt, 
potassium chloride, bovine serum albumin (BSA), glutaraldehyde, dopamine 
hydrochloride (DA), L-ascorbic acid (AA), and DPX were obtained from Sigma-Aldrich Co. 
(St. Louis, MO). Rabbit polyclonal glial fibrillary acidic protein antibody (GFAP) was 
obtained from Dako. Guinea pig polyclonal VGLUT1 antibody was obtained from 
Millipore. Biotinylated goat anti-rabbit serum, biotinylated goat anti-guinea pig serum, 
avidin-biotin complex (ABC) kit, and VIP peroxidase substrate kit were obtained from 
Vector Laboratories.  
2.3  Morris water maze 
The MWM tests spatial learning and memory by requiring the mouse to utilize visual 
clues for locating a static, submerged platform, regardless of the starting quadrant as 
previously reported20.  The MWM paradigm consists of 5 consecutive learning days with 
three, 90 s trials/day and a minimum of 20 min between trials.  After two days without 
testing, mice are given a single, 60 s probe challenge to test memory.  The ANY-maze 
video tracking system (Stoelting Co., Wood Dale, IL) records and analyzes duration in 
each quadrant, distance traveled, average speed, and path efficiency for the 5 learning 
days.  Additional parameters analyzed for the single probe trial include the number of 
platform crosses, time in annulus 40, latency, distance, and path efficiency to first platform 
cross. 
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2.4.  In Vivo Glutamate Measurements 
2.4.1  Enzyme-Based Microelectrode Arrays   
Enzyme-based MEAs with platinum (Pt) recording surfaces (Figures 1A & B) were 
fabricated, assembled, coated, and calibrated for in vivo mouse glutamate 
measurements22,26,27.  Briefly, one of the R2 MEA Pt sites was coated with an L-glutamate 
oxidase, BSA and glutaraldehyde coating solution.  BSA and glutaraldehyde increase the 
adhesion and crosslink L-glutamate oxidase to the MEA surface.  L-glutamate oxidase 
causes the enzymatic breakdown of glutamate to α-ketoglutarate and the electroactive 
reporter molecule, H2O2. The second Pt recording site (self-referencing or sentinel site) 
was coated similar to the glutamate recording site, except L-glutamate oxidase was 
omitted from the coating solution; therefore, the sentinel site was unable to enzymatically 
generate H2O2 from L-glutamate. A potential of +0.7V vs a Ag/AgCl reference electrode 
was applied to the Pt recording surface, resulting in a two electron oxidation of H2O2 and 
the current was amplified and digitized by the Fast Analytical Sensing Technology (FAST) 
16mkIII (Quanteon, LLC; Nicholasville, KY) electrochemistry instrument.   
2.4.2  mPD Electropolymerization 
A minimum of 72 hrs after enzyme coating, all Pt recording surfaces were electroplated 
with 5 mM mPD in 0.05 M phosphate buffered saline (PBS)28.  FAST electroplating 
software applied a potential as a triangular wave with an offset of -0.5V, peak-to-peak 
amplitude of 0.25V, at a frequency of 0.05 Hz, for 20 min to create a size exclusion layer 
that restricts the passage of AA, DA, uric acid and 3,4-dihydroxyphenylacetic acid.    
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2.4.3  Calibration 
A minimum of 24 hrs after mPD electropolymerization, each MEA was calibrated in vitro 
prior to implantation to generate a standard curve for the conversion of current to 
glutamate concentration29.  The Pt recording sites and a glass Ag/AgCl reference 
electrode (Bioanalytical Systems, Inc., West Lafayette, IN) were placed in a continuously 
stirred solution of 0.05 M PBS (40.0 mL) maintained at 37°C with a recirculating water 
bath (Stryker Corp., Kalamazoo, MI).  Final beaker concentrations of 250 µM AA, 20, 40, 
and 60 µM L-glutamate, 2 µM DA, and 8.8 µM H2O2 were used to assess MEA 
performance (Figure 1C).  A total of 18 MEAs (13 unique) were used in the present study. 
The average ± standard error of the mean (SEM) for glutamate sensitivity was 9.7 ± 1.0 
pA/μM (R2 = 0.995 ± 0.003), selectivity ratio of 805 ± 327 to 1, and limit of detection of  
0.45 ± 0.26 μM based on a signal-to-noise ratio of 3. 
2.4.4  Microelectrode Array / Micropipette Assembly 
A glass micropipette (1.0 mm outer diameter, 0.58 mm internal diameter; World Precision 
Instruments, Inc., Sarasota, FL) was used to locally apply solutions to the mouse 
hippocampal subfields.  Glass micropipettes were pulled using a vertical micropipette 
puller (Sutter Instrument Co., Novato, CA) and the tip was ‘bumped’ to create an internal 
diameter of 12-15 µm.  The tip of the micropipette was positioned between the pair of 
recording sites and mounted 100 µm above the MEA surface.  The micropipettes were 
filled with sterile filtered (0.20 µm) 70 mM KCl (70 mM KCl, 79 mM NaCl and 2.5 mM 
CaCl2, pH 7.4).  Fluid was pressure-ejected from the glass micropipette using a 
Picospritzer III (Parker-Hannafin, Cleveland, OH), with pressure (5-15 psi) adjusted to 
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consistently deliver volumes between 100-200 nl over 1-2 s intervals.  Ejection volumes 
were monitored with a stereomicroscope (Luxo Corp., Elmsford, NY) fitted with a 
calibrated reticule30. 
2.4.5 Reference Electrode 
A Ag/AgCl reference electrode was prepared by stripping 5 mm of Teflon from each end 
of a silver wire (200 μm bare, 275 μm coated; A-M Systems, Carlsberg, WA). One of the 
stripped ends was soldered to a gold-plated test connector (Newark element14 Chicago, 
IL) and the other end was coated with AgCl by placing the tip of the stripped sliver wire 
(cathode) into a 1 M HCl plating bath saturated with NaCl containing a stainless steel wire 
(anode) and applying +9 V DC using a power supply to the cathode versus the anode for 
15 min. 
2.5 In Vivo Anesthetized Recordings 
At least one week following the MWM probe challenge, mice were anesthetized using 
1.5-2.0% isoflurane (Abbott Lab, North Chicago, IL) from a calibrated vaporizer (Parkland 
Scientific, Inc., Coral Springs, FL) and prepared for in vivo electrochemical recordings 
(Hascup & Hascup, 2014).  The mouse was placed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, CA) fitted with a mouse anesthesia mask and body temperature 
was maintained at 37°C with a hydrothermal pad connected to a recirculating water bath.  
A craniotomy was performed to access the DG (AP: -2.0, ML: ± 1.0, DV: -2.2 mm), CA3 
(AP: -2.0, ML: ± 2.0, DV: -2.2 mm), and CA1 (AP: -2.0, ML: ± 1.0, DV: -1.7 mm) from 
Bregma based on the coordinates of Paxinos and Franklin31.  A Ag/AgCl reference wire 
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was implanted in the right cortex, remote from the recording area.  The MEA / micropipette 
assembly was lowered into the DG, CA3, or CA1 (hippocampal subfield and hemisphere 
randomly assigned for each mouse) using a microdrive (Narishige International, East 
Meadow, NY) attached to the electrode holder of the stereotaxic arm.   Constant potential 
amperometry (4Hz) was performed using the FAST16mkIII and FAST software for multi-
channel simultaneous recordings32.  MEAs were allowed to reach a stable baseline for 60 
min, at which time basal glutamate measures were taken (ten second average) followed 
by pressure ejection studies.  All values for pressure ejections refer to changes versus 
baseline. After pressure ejection studies, brains were removed and fixed in 4% 
paraformaldehyde followed by 0.1 M phosphate buffer containing 30% sucrose for at least 
24 hours before cryosectioning for immunohistochemistry (45 μm). 
2.6 Immunohistochemical Staining and Semiquantification 
Immunohistochemistry in the hippocampus was performed using rabbit polyclonal  GFAP 
(1:2000) or guinea pig polyclonal VGLUT1 antibody (1:1,000). Briefly, primary antibodies 
were applied to serial sections taken for every sixth section from the hippocampus based 
on our previous protocols33. Endogenous peroxidase activity was quenched by treating 
sections with 10% H2O2 in 20% methanol for 10 minutes. Sections were then 
permeabilized in TBST (Tris-buffered saline with 0.25% TritonX-100) following treatment 
for 20 minutes with sodium metaperiodate. Non-specific binding was controlled by 
incubation in 10% normal goat serum for 1 hour. Sections were then incubated overnight 
in the primary antibody at room temperature. The next day, sections were incubated for 
1 hour with the secondary antibody (1:200; biotinylated goat anti-rabbit serum or 
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biotinylated goat anti-guinea pig serum) and 1 hour with the ABC kit. The reaction was 
developed using the VIP peroxidase substrate kit to enhance the reaction and produce a 
color stain. This reaction was stopped using 0.1 M phosphate buffer, and the sections 
were mounted on glass slides, dehydrated, and cover-slipped with DPX. To control for 
staining intensity, staining of all sections for each antibody were conducted on the same 
day, and developed with VIP for the same amount of time (GFAP: 3 minutes, VGLUT-1: 
2 minutes). 
Staining intensity of GFAP and VGLUT-1 in the hippocampus was determined using 
National Institutes of Health Image J Software 1.48 to measure a gray scale value within 
the range of 0–256, where 0 represents white and 256 black. A template for the DG, CA3, 
and CA1 subregions of the hippocampus was created and used on all brains similarly, 
and images were captured with a Nikon Eclipse E-600 microscope equipped with an 
Olympus-750 video camera system, and a Dell Pentium III computer. Measurements 
were performed blinded and approximately 6 sections were averaged to obtain 1 value 
per subject. Staining density was obtained when background staining was subtracted 
from mean staining intensities on every sixth section through the hippocampus.  
2.7  Data Analysis 
The FAST16MkIII electrochemical instrument and FAST software saves amperometric 
data, time and pressure ejection events for all Pt recording sites.  Calibration data, in 
conjunction with a MATLAB (MathWorks, Natick, MA) graphic user interface program 
developed by Jason Burmeister Consulting, LLC (Version 6.1) was used to calculate 
basal glutamate and 70 mM KCl-evoked glutamate release and uptake.  To determine 
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extracellular glutamate concentration, the sentinel site current (pA) was subtracted from 
the glutamate recording site current (pA) and divided by the slope (pA/µM) obtained 
during the calibration32,34–36.  Basal glutamate was calculated by taking a 10 s baseline 
average prior to start of pressure ejection in the DG, CA3, and CA1.  For stimulus-evoked 
glutamate studies, five reproducible signals were obtained in each hippocampal subfield.  
These signals were then averaged into a single data point for each hippocampal subfield 
per mouse for comparison between genotypes.  Glutamate uptake followed first-order-
rate kinetics; therefore the uptake rate constant (k−1) was calculated as the logarithmic 
slope of glutamate concentration versus time (s−1) estimated by use of regression 
analyses (R2≥0.9). Because of different cell types and afferent inputs, hippocampal 
subfields were analyzed independently.  Prism software (GraphPad Software, Inc., La 
Jolla, CA) was used for all statistical analyses.  A two-way Analysis of Variance (ANOVA) 
with Tukey’s multiple comparison’s post-hoc test was used to analyze MWM training data.  
An unpaired, two-tailed Student’s t-test was used to analyze MWM probe, 
electrochemical, and immunohistochemical data in each hippocampal subfield.  
Comparisons between MWM and glutamate electrochemical data were established 
using Pearson correlation.  Outliers, determined using Grubbs’ test with alpha = 0.05, 
were removed prior to analysis (no more than one per genotype).   Data are represented 
as mean ± SEM and significance was defined as p<0.05.  
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3.  Results 
3.1  MWM Training and Probe Challenge 
Learning and memory was assessed using an 8 day MWM behavioral paradigm as 
described in section 2.420.  A significant increase by the fifth training day, relative to the 
first training day, in the path efficiency (F(4,72) = 13.72; p<0.0001) to reach the hidden 
escape platform was observed for the littermate controls and GHR-KO mice with no 
differences observed between the two genotypes on any day (Figure 2A); indicating that 
both genotypes were able to consolidate memories and there were no learning-related 
genotypic differences.  During the probe challenge littermate controls took a less efficient 
path (0.16 ± 0.04; F(9,9) = 2.844; p = 0.0280) to first platform entry compared to GHR-
KO mice (0.37 ± 0.07, respectively); indicating littermate controls had impaired memory 
(Figure 2B).  Representative probe challenge tracks for littermate controls and GHR-KO 
mice are shown in figures 2C & D, respectively.     
3.2  Basal Glutamate 
Prior to stimulus-evoked glutamate release, basal glutamate measures were assessed in 
each of the hippocampal subfields.  Littermate control basal glutamate (Figure 3A) was 
elevated compared with GHR-KO mice in the DG (2.6 ± 0.5 µM, 0.9 ± 0.3 µM; F(6,6) = 
3.582; p = 0.0099), CA3 (3.1 ± 0.4 µM, 1.2 ± 0.4 µM; F(6,6) = 1.232; p = 0.0029) and CA1 
(4.3 ± 0.8 µM, 1.2 ± 0.5 µM; F(7,6) = 3.134; p = 0.0055).  A negative correlation (r = -
0.5619; p = 0.0365) was observed between CA3 basal glutamate and path efficiency to 
first platform entry during the MWM probe trial (Figure 3B). 
3.3  Stimulus-Evoked Glutamate Release 
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We locally applied consistent volumes of 70 mM KCl to littermate controls and GHR-KO 
mice in the DG (158 ± 7 nl, 147 ± 4 nl; F(9,7) = 3.555; p = 0.2008), CA3 (152 ± 5 nl, 155 
± 10 nl; F(9,7) = 2.447; p = 0.8040), and CA1 (149 ± 6 nl; 153 ± 5 nl; F(9,6) = 1.560; p = 
0.6239) to evoke glutamate release (Figure 4A).  As shown in Figure 4B, local application 
of 70 mM KCl elicited robust, reproducible glutamate signals in the CA3 of littermate 
controls and GHR-KO mice.  These glutamate signal patterns were observed in all three 
hippocampal subfields studied.  The average maximal stimulus-evoked glutamate release 
was significantly elevated in the littermate controls versus GHR-KO mice in the DG (4.9 
± 1.0 µM, 2.3 ± 0.5 µM; F(9,7) = 3.984; p = 0.0452), CA3 (9.1 ± 0.9 µM, 3.7 ± 0.5 µM; 
F(9,7) = 4.772; p = 0.0002) and CA1 (3.7 ± 0.6 µM, 2.0 ± 0.2 µM; F(9,6) = 12.91; p = 
0.0332) as shown in Figure 4C.  No statistical differences between stimulus-evoked 
glutamate uptake was observed between the littermate controls and GHR-KO mice in DG 
(0.4 ± 0.2 µM/sec, 0.7 ± 0.2 µM/sec; F(8,7) = 1.647; p = 0.3392), CA3 (2.0 ± 0.5 µM/sec, 
1.1 ± 0.3 µM/sec; F(9,7) = 3.263; p = 0.1470), or CA1 (0.6 ± 0.2 µM/sec, 0.7 ± 0.3 µM/sec; 
F(8,7) = 2.673; p = 0.4228) (Figure 4D).  
3.4 Histological Assessment 
Littermate control GFAP (Figure 5A) was decreased compared with GHR-KO mice in the 
DG (10.6 ± 1.3, 15.3 ± 1.3; F(8,7) = 1.121; p = 0.0236), CA3 (12.7 ± 0.5, 15.9 ± 1.0; F(7,8) 
= 3.089; p = 0.0096), and CA1 (8.7 ± 0.6, 12.5 ± 0.8; F(7,8) = 1.684; p = 0.0016). 
Representative images of GFAP staining in whole hippocampus for littermate controls 
and GHR-KO mice are shown in Figures 5B and C, respectively.  Magnified images of 
the DG, CA3, and CA1 for littermate controls (5D, F, and H, respectively) and GHR-KO 
mice (Figures 5E, G, and I, respectively) are presented. We observed hippocampal brain 
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region and genotype dependent changes in VGLUT1 staining. Littermate controls 
VGLUT1 (Figure 6A) was decreased compared to GHR-KO mice in the DG (4.5 ± 0.6, 
12.3 ± 0.8; F(7,8) = 1.633; p <0.0001), no change in the CA3 (6.8 ± 0.8, 8.7 ± 1.0; F(7,8) 
= 1.163; p = 0.1476), and increased in the CA1 (8.2 ± 0.9, 5.2 ± 0.5; F(8,7) = 3.997; p = 
0.0133).  Representative images of VGLUT1 staining in the DG, CA3, and CA1 of 
littermate controls and GHR-KO mice are shown in Figures 6B-G.   
 
4. Discussion 
The glutamatergic system plays an important role in age-related cognitive decline and 
cognitive disorders, and that tight regulation of glutamate is essential for normal 
brain/cognitive function. Generally, the two major means of controlling both tonic and 
phasic glutamate neurotransmission are through glutamate release and uptake. Under 
normal conditions, glutamate release is primarily accomplished through depolarization of 
glutamatergic neurons, which can be identified by the presence of VGLUTs located at the 
terminals. Glial cells, composed of astrocytes and microglia, are predominantly 
responsible for clearance of glutamate from the extracellular space mediated through 
surface expression of excitatory amino acid transporters (EAATs).  One EAAT, Glt-1 
(EAAT2 in humans), is responsible for ~90% of glutamate clearance from the extracellular 
space37.  Additionally, Glt-1 surface expression and function decrease with age, possibly 
leading to excitotoxicity, which may be exacerbated in age-related cognitive disorders, 
further supporting the importance of proper glutamate system maintenance for cognitive 
retention in advanced age17.  We have previously reported on age-related changes in 
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glutamatergic markers, including elevated mRNA expression of GLT-1 and retained 
VGLUT1 levels in the hippocampus of long lived GHR-KO mice compared to age-
matched littermate controls12.  In the present study, we examine cognition and 
glutamatergic neurotransmission dynamics to elucidate the role of glutamate in GHR-KO 
mice that exhibit enhanced cognition in old age compared to age-matched littermate 
controls. 
Our MWM data supports that 20-24 month-old littermate controls and GHR-KO mice learn 
to locate the hidden escape platform, indicating no differences in memory consolidation.  
However, after a 48 hour delay, littermate controls present with impaired memory retrieval 
compared to GHR-KO mice during the probe challenge of the task.  While it is well known 
that memory retention declines with age in mice38,39, previous studies utilizing the 
inhibitory avoidance, open field, and MWM tasks indicate memory retrieval in GHR-KO 
mice does not decline with age40–42.  This may be the result of more stringent regulation 
of the glutamate system in the hippocampus, as supported by our previous findings12. 
Therefore, a possible explanation for improved memory retrieval in GHR-KO mice is that 
they experience delayed aging thereby postponing the onset of cognitive decline40.   
The dorsal hippocampus is important for consolidation and retrieval of spatial memory 
during the MWM task21. Hippocampal inhibition of the EAATs, and therefore decreased 
glutamate clearance, has been shown to induce long term depression (LTD) mediated 
through elevated extrasynaptic glutamate binding to the GluN2B-NMDA receptor 
subtype43 and negatively impacting cognition.    In support of this, we observed a negative 
correlation between CA3 basal glutamate and path efficiency to first platform entry on the 
MWM task, however, this correlation was not observed with DG or CA1 basal glutamate.  
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This may be due to of the importance of mossy fiber projections to the CA3 subfield for 
memory consolidation and retrieval in spatial navigation tasks44,45.  Therefore, the 
increased availability of basal glutamate to activate GluN2B in the CA3 may contribute to 
the cognitive decline observed in littermate controls while the corollary is true in the GHR-
KO mice. Furthermore, we observed elevated GFAP staining in the hippocampus of GHR-
KO mice indicating an increase in glia, which likely contributed to the overall decrease in 
glutamatergic tone in these mice. 
We observed decreased evoked release of glutamate in GHR-KO mice in all three 
hippocampal subregions examined compared to age-matched littermate controls. This 
may be explained by previous reports12 of an age-related decrease in VGLUT1 mRNA 
levels from whole hippocampus in littermate controls, but not GHR-KO mice.   Further 
evaluation of 20-24 month old female GHR-KO and littermate control mice presented in 
the current manuscript using histological techniques revealed hippocampal subregion 
dependent changes in VGLUT1. However, this is contradictory to our evoked glutamate 
release data where littermate controls exhibited elevated glutamate release compared to 
GHR-KO mice. This likely indicates a disconnect between the number of glutamate 
terminals (VGLUT1) and the inherent excitability of the neurons (stimulated release). It is 
also possible that the anesthetic used during our glutamate recordings (isoflurane) 
preferentially suppressed KCl-evoked glutamate release in GHR-KO mice. However, this 
is highly unlikely because isoflurane dosage was kept consistent (1.5-2.0%) between 
mice. Furthermore, GHR-KO mice have a higher metabolic rate than their littermate 
controls and therefore would metabolize isoflurane more quickly, if anything, thereby 
having less anesthetic-related alterations.  
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Since basal glutamate levels are regulated by a combination of continuous release and 
uptake, we are not able to directly measure clearance kinetics as we can with stimulus-
evoked glutamate release.  However, we did not observe any difference in 70 mM KCl-
evoked glutamate uptake between genotypes in any of the hippocampal subfields studied 
despite a significant difference in GFAP levels, possibly because there was sufficient 
GLT-1 present in close proximity and functioning adequately enough to quickly clear 
evoked glutamate released from both genotypes. We observed significantly more GFAP 
in all three hippocampal subregions examined in GHR-KO mice compared to littermate 
controls. It is possible that the increased energy demands of GHR-KO mice compared to 
littermate controls46 may lead to an increase in astrocytes (the main location of glycogen 
in the brain) to ensure that the brain has sufficient energy, with glutamate uptake into 
astrocytes contributing to the store of available energy47,48. While an increase in GFAP 
does not always indicate elevated GLT-1, our previous data indicate elevated GLT-1 
mRNA in GHR-KO hippocampus12. Since GLT-1 accounts for 90% of glutamate uptake37, 
a decrease in this transporter may slow glutamate clearance, leading to the elevated 
basal glutamate observed in the littermate controls. However, it should be noted that 
mRNA levels do not necessarily correspond to protein levels or even surface expression 
and it is possible that experimental design limitations may have contributed to this 
discrepancy between elevated GFAP and GLT-1, but no differences in the uptake rate of 
evoked release of glutamate.  First, EAATs are electrogenic and membrane 
depolarization slows glutamate uptake49.  Second, isoflurane, the anesthetic used in this 
study, increases glutamate uptake through GLT-150.   Although, the amount of stimulus 
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and anesthetic were consistent in all mice, it is possible that the combination of these two 
phenomena could alter GLT-1 such that their effects overshadow differences in 
transporter number when measured with our recording technique.   
Additionally, glucocorticoids may contribute to elevated basal and stimulus-evoked 
glutamate release in the littermate control mice.  Glucocorticoids have the potential to 
increase basal glutamate levels in the hippocampus and impair memory through binding 
of glutamate to the GluN2B containing NMDA receptor51, which may also be affected by 
isoflurane.  While Huack and colleagues52 demonstrated there was no difference in 
corticosterone levels in 4-5 month old female GHR-KO and littermate control mice under 
stressed and non-stress conditions, to date glucocorticoid levels have not been examined 
in aged female GHR-KO mice.  Previous studies support that glucocorticoid levels 
increase as female mice age contributing to age-related bone loss53.  Considering GHR-
KO mice are a model of delayed aging, it goes to reason that glucocorticoid levels may 
be increased in littermate controls compared to GHR-KO mice, potentially contributing to 
the elevated extracellular glutamate observed in this study. 
In summary, we have demonstrated that littermate controls have impaired cognition and 
hyperglutamatergic signaling in the DG, CA3, and CA1 hippocampal subfields compared 
to GHR-KO mice.  Cognitive performance on the MWM behavioral task was predicted by 
CA3, but not DG or CA1, basal glutamate and elevated GFAP observed in GHR-KO mice 
may be neuroprotective by contributing to decreased basal glutamate levels.  Taken 
together, these data and our recent reports of elevated evoked glutamate release in the 
hippocampus of APP/PS1 mice, a model of Alzheimer’s disease20, support an 
overarching theme whereby elevated hippocampal glutamate is associated with cognitive 
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impairment and maintenance of the glutamatergic system throughout life is essential for 
the preservation of cognition in aging and age-related neurodegenerative disorders. 
Furthermore, these data support the importance of glutamatergic regulation for learning 
and memory in the GHR-KO mouse model of successful aging that may relate to cognitive 
resilience and could have implications as therapeutic targets to delay the onset of, or 
reduce cognitive decline, in several diseases and disorders, including Alzheimer’s 
disease. 
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Figure Legends:  
Figure 1:  MEA and In Vitro Calibration.  A) Image of the R2 MEA used for anesthetized 
recordings with a ruler for scale comparison and (B) magnified tip depicting 2 Pt recording 
sites, each measuring 50 x 100 µm with 100 µm spacing between sites.  C) A typical MEA 
in vitro calibration measuring the change in current on a glutamate measuring site (black) 
and a sentinel recording site (gray) with the addition of multiple analytes, as indicated (↓).  
The addition of interferents such as AA and DA produced no current change on either site 
since they are blocked by the mPD exclusion layer.  Three glutamate additions showed 
a stepwise increase of current on the glutamate oxidase / BSA / glutaraldehyde site, but 
no response on the BSA / glutaraldehyde sentinel site.  The addition of H2O2 produced a 
similar increase of current on both recording sites demonstrating equivalent functionality. 
 
Figure 2:  Memory Impairment in Littermate Controls. MWM training sessions 
indicates path efficiency (A) to locate the hidden platform was significantly increased over 
time for littermate controls and GHR-KO mice (n=10 per group).  By the fifth training 
session both genotypes took similar durations and distances to reach the platform 
indicating comparable learning.  Two-way ANOVA indicates a significant (p<0.001) effect 
of training day.  **p<0.01, ***p<0.001 vs GHR-KO training day 1 and §§§§p<0.0001 vs 
littermate control training day 1 based on a Tukey’s multiple comparison post-hoc.  MWM 
probe challenge indicates littermate controls took a less efficient path (B) to first platform 
entry compared to GHR-KO mice. Two-tailed Student’s t-test (n = 10 mice per group), 
*p<0.05.  Representative MWM probe tracks from littermate controls (C) and GHR-KO 
mice (D).   The small circle represents the previous location of the hidden escape platform 
while the circle surrounding the platform represents the annulus 40. 
Figure 3:    Elevated CA3 Basal Glutamate Predicts MWM Impairments. A) Bar graphs 
depicting elevated basal glutamate in all hippocampal subfields of littermate controls 
compared to GHR-KO mice.  Two-tailed Student’s t-test (n = 7-8 mice per group) 
**p<0.01.  B) Correlation of CA3 basal glutamate with MWM probe path efficiency to first 
platform entry for littermate controls (open circles) and GHR-KO mice (dark squares).  
Dashed line represents the least squares regression. 
Figure 4:  Stimulus-Evoked Glutamate Release and Uptake. A) Bar graph depicting a 
similar range of 70 mM KCl (stimulus) was used to elicit glutamate release in all 
hippocampal subfields of both mouse genotypes.  B)  Representative traces of local 
application (↑) of 70 mM KCl-evoked glutamate release in the CA3 of littermate controls 
(top, gray) and GHR-KO (bottom, black) mice.  C)  Bar graphs of average maximal evoked 
glutamate was elevated in all hippocampal subfields of littermate controls compared to 
GHR-KO mice.  D) Glutamate uptake rate was not significantly different between 
genotypes in any of the 3 hippocampal subfields.  Two-tailed Student’s t-test (n = 7-10 
mice per group), *p<0.05, ***p<0.001. 
Figure 5:  Hippocampal GFAP Levels. Histological staining of GFAP in the 
hippocampus of littermate controls and GHRKO mice. A) Bar graph of GFAP average 
mean density was elevated in all hippocampal subfields of GHR-KO mice compared to 
littermate controls. Two-tailed Student’s t-test (n = 8-9 mice per group),*p<0.05, **p<0.01. 
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Representative images of GFAP staining in whole hippocampus for littermate controls (B) 
and GHR-KO mice (C) (scale bar is 100 µm).  Representative magnified images of 
littermate control and GHR-KO mice DG (D, E, respectively), CA3 (F, G, respectively), 
and CA1 (H, I, respectively) (scale bar is 50 µm). 
Figure 6:  Hippocampal VGLUT1 Levels. Histological staining of VGLUT1 in the 
hippocampus of littermate controls and GHRKO mice. A) Bar graph of VGLUT1 average 
mean density in littermate controls was decreased compared to GHR-KO mice in the DG, 
no change in the CA3, and increased in the CA1. Two-tailed Student’s t-test (n = 8-9 mice 
per group),*p<0.05, ****p<0.0001. Representative images of littermate control and GHR-
KO mice DG (B, C, respectively), CA3 (D, E, respectively), and CA1 (F, G, respectively). 
Scale bar is 25 µm. 
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